Skip to content

Tarsus Pharmaceuticals

US · TARS #2389 by market cap Listed 2020
73.01 -4.66 -6.00%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 75.54 -2.74%
After-hours 71.00 -2.75%
90.7856.1173.012026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on TARS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -1.5% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 13.0% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall B

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 93.2% Better than 97%
Operating margin -15.7% Better than 13%
Net margin -14.7% Better than 14%
Return on equity -23.4% Better than 15%
Return on invested capital -20.2% Better than 13%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 0.4% Better than 74%
6-month return 17.3% Better than 80%
12-month return (ex latest month) -9.5% Better than 23%
Distance below 52-week high 20.2% Better than 60%
Financial Health B

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.9x Better than 80%
Debt to assets 12.9% Better than 65%
Interest coverage -6.7x Better than 15%
Analyst View A-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 44.6% Better than 63%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -9.06%
1M +2.79%
3M +2.13%
6M +12.69%
YTD -10.83%
1Y -5.16%
3Y +317.20%
5Y +191.22%

Key statistics

Price & volume

Prev close
77.67
Open
77.09
Day range
72.57 - 78.11
Avg price
73.83
Volume
706.77K
Turnover
52.18M
Amplitude
7.13%
52-week range
53.89 - 91.53

Valuation

P/E
-45.92
P/E (TTM)
-4.60
P/B
34.60
EPS
-1.59
Net profit
-78.40M
Net assets
104.03M

Share structure

Market cap
3.60B
Float cap
2.97B
Shares out
49.31M
Float shares
40.67M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-10-16
52-week range 51% of range
53.89 91.53

20.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-15.87M net over the window

Short interest

Shares short
6.07M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Tarsus Pharmaceuticals (TARS)?

Tarsus Pharmaceuticals last traded at 73.01. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Tarsus Pharmaceuticals's market cap?

About 3.60B.

What is the P/E ratio of Tarsus Pharmaceuticals?

The trailing twelve-month P/E is -4.60. The Valuation tab shows it against the stock's own five-year range.

Does Tarsus Pharmaceuticals pay a dividend?

Tarsus Pharmaceuticals does not currently pay a regular dividend.

Is Tarsus Pharmaceuticals a buy according to analysts?

The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 105.57, which implies 44.6% upside from the current price. This is not investment advice.

What is Tarsus Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Tarsus Pharmaceuticals a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.

Tarsus Pharmaceuticals discussion 0 comments

Add a comment